Global Leukemia Therapeutic Market Research and Analysis, 2014-2020
Market Insight:
Global Leukemia Market is expected to exceed $8.6 billion in 2020 with a CAGR 8.8% during 2015-2020. Leukemia is a lingering disease prevalent across the globe with huge economic burden in emerging and low-middle income group countries. It has considerable presence in developed and developing economies such as US, UK, Spain, China, India and Korea. North America and Europe generates highest revenues across the globe due to huge number of leukemia patients and highest rate of healthcare spending. APAC region such as China, India, Japan and Korea are predicted to offer variety of opportunities for leukemia market due to improved healthcare spending, infrastructure and favorable government policies. The report also includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.
The market is expected to perform significantly due to advancement in leukemia therapeutics, research & development, funding from government and private players and successful clinical trials. Untapped APAC region is the most emerging market with highest CAGR during 2015-2020. However, the high cost of leukemia therapeutic and less awareness among key regions is a concern for the growth of leukemia market in emerging and low-middle income group countries.
The report also covers various factors that influence the market for example the government regulations, drug and device laws and regulations, regulations on clinical trials, government policies and so on are covered at length. The report also covers type of Leukemia, historical analysis and diagnosis extensively with latest update on pipeline products in pipeline analysis. The diagnosis of leukemia includes health and physical exam, Complete Blood Count, Biopsy and Bone Marrow Aspiration, Blood Chemistry Test, Cytochemistry, CT scan, X-ray, MRI, Ultrasound and so on. Leukemia is the growing market the key therapies of leukemia therapeutics include chemotherapy, stem cell transplant, radiation therapy, targeted therapy, watchful waiting and supportive therapy.
COMPETITIVE INSIGHTS:
The key players of Leukemia Therapeutic market includes Clavis Pharma ASA, Pfizer, Ambit, Novartis, Bristol, Genzyme, Celgene Cephalon, Innate Pharma and so on. Leukemia market has huge opportunity for the new entrants and established players since the FDA nod to recent leukemia drugs created huge demand for leukemia drugs. Every leukemia company has huge investment in research & development. The successful clinical trials of leukemia drugs are expected to get FDA approval in near future. Bosulif (Pfizer), Rituximab (Innate Pharma), Tasigna (Novartis) and various other drugs are in pipeline and expected to get FDA nod in near future.
Global Leukemia Market is expected to exceed $8.6 billion in 2020 with a CAGR 8.8% during 2015-2020. Leukemia is a lingering disease prevalent across the globe with huge economic burden in emerging and low-middle income group countries. It has considerable presence in developed and developing economies such as US, UK, Spain, China, India and Korea. North America and Europe generates highest revenues across the globe due to huge number of leukemia patients and highest rate of healthcare spending. APAC region such as China, India, Japan and Korea are predicted to offer variety of opportunities for leukemia market due to improved healthcare spending, infrastructure and favorable government policies. The report also includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.
The market is expected to perform significantly due to advancement in leukemia therapeutics, research & development, funding from government and private players and successful clinical trials. Untapped APAC region is the most emerging market with highest CAGR during 2015-2020. However, the high cost of leukemia therapeutic and less awareness among key regions is a concern for the growth of leukemia market in emerging and low-middle income group countries.
The report also covers various factors that influence the market for example the government regulations, drug and device laws and regulations, regulations on clinical trials, government policies and so on are covered at length. The report also covers type of Leukemia, historical analysis and diagnosis extensively with latest update on pipeline products in pipeline analysis. The diagnosis of leukemia includes health and physical exam, Complete Blood Count, Biopsy and Bone Marrow Aspiration, Blood Chemistry Test, Cytochemistry, CT scan, X-ray, MRI, Ultrasound and so on. Leukemia is the growing market the key therapies of leukemia therapeutics include chemotherapy, stem cell transplant, radiation therapy, targeted therapy, watchful waiting and supportive therapy.
COMPETITIVE INSIGHTS:
The key players of Leukemia Therapeutic market includes Clavis Pharma ASA, Pfizer, Ambit, Novartis, Bristol, Genzyme, Celgene Cephalon, Innate Pharma and so on. Leukemia market has huge opportunity for the new entrants and established players since the FDA nod to recent leukemia drugs created huge demand for leukemia drugs. Every leukemia company has huge investment in research & development. The successful clinical trials of leukemia drugs are expected to get FDA approval in near future. Bosulif (Pfizer), Rituximab (Innate Pharma), Tasigna (Novartis) and various other drugs are in pipeline and expected to get FDA nod in near future.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. INCIDENCE & PREVALENCE RATE
2.4. HISTORICAL ANALYSIS
2.5. PIPELINE ANALYSIS
2.5.1. ARZERRA (NOVARTIS)
2.5.2. TASIGNA (NOVARTIS)
2.5.3. CTL019(NOVARTIS)
2.5.4. BOSULIF (PFIZER)
2.5.5. INOTUZUMAB OZOGAMICIN (PFIZER)
2.5.6. SMO INHIBITOR: ACUTE MYELOID LEUKEMIA (PFIZER)
2.5.7. IMBRUVICA (JOHNSON & JOHNSON)
2.5.8. AG-221 (AGIOS)
2.5.9. LIRILUMAB (INNATE PHARMA)
2.5.10. RITUXIMAB (INNATE PHARMA)
2.6. LEUKEMIA TYPE
2.7. LEUKEMIA DIAGNOSIS
2.7.1. HEALTH HISTORY AND PHYSICAL EXAM
2.7.2. COMPLETE BLOOD COUNT (CBC)
2.7.3. BIOPSY AND BONE MARROW ASPIRATION
2.7.4. BLOOD CHEMISTRY TESTS
2.7.5. BLEEDING & CLOTTING FACTORS
2.7.6. CYTOCHEMISTRY
2.7.7. IMMUNOPHENOTYPING
2.7.8. CYTOGENTIC & MOLECULAR STUDIES
2.7.9. LUMBUR NODE BIOPSY
2.7.10. PHILADELPHIA CHROMOSOME’S PRESENCE
2.7.11. LUMBAR PUNCTURE & CEREBROSPINAL FLUID (CSF) ANALYSIS
2.7.12. IMMUNOPHENOTYPING OR PHENOTYPING BY FLOW CYTOMETRY
2.7.13. POLYMERASE CHAIN REACTION (PCR)
2.7.14. X-RAY, CT-SCAN, MRI, ULTRASOUND
2.8. KEY LEUKEMIA THERAPIES
2.8.1. CHEMOTHERAPY
2.8.2. STEM CELL TRANSPLANT
2.8.3. RADIATION THERAPY
2.8.4. TARGETED THERAPY
2.8.5. WATCHFUL WAITING
2.8.6. SUPPORTIVE THERAPY
2.8.7. OTHERS
2.9. CURRENT MARKET TRENDS
2.10. ANALYST INSIGHT
2.10.1. KEY FINDINGS
2.10.2. RECOMMENDATION
2.10.3. CONCLUSION
2.11. REGULATION
2.11.1. REGULATIONS ON CLINICAL TRIALS
2.11.1.1. FDA REGULATIONS
2.11.1.1.1. UNITED STATES
2.11.1.1.2. EUROPEAN UNION
2.11.1.1.3. CHINA
2.11.1.1.4. INDIA
2.11.1.1.5. REST OF THE WORLD
2.11.1.2. DRUG AND DEVICE REGULATIONS
2.11.1.2.1. UNITED STATES
2.11.1.2.2. EUROPEAN UNION
2.11.1.2.3. CHINA
2.11.1.2.4. INDIA
2.11.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. FDA NOD TO LEUKEMIA DRUGS ARE DRIVING THE MARKET
3.1.2. SUCCESS OF RESEARCH AND DEVELOPMENT IN LEUKEMIA THERAPEUTIC AND DRUGS
3.1.3. ADVANCEMENT IN CANCER THERAPEUTICS TO BOOST GLOBAL LEUKEMIA THERAPEUTIC MARKET
3.1.4. RISE IN ADOPTION OF PERSONALIZED MEDICINE IN THE GLOBAL LEUKEMIA THERAPEUTIC MARKET
3.1.5. INCREASE IN INCIDENCE PREVALENCE RATE OF LEUKEMIA DISEASES
3.2. RESTRAINT
3.2.1. HIGH COST OF LEUKEMIA THERAPEUTICS IS A CONCERN
3.2.2. LESS POPULAR IN EMERGING AND UNDER DEVELOPED COUNTRIES
3.3. OPPPORTUNITY
3.3.1. RISE IN ELDERLY POPULATION ACROSS THE GLOBE
3.3.2. SUCCESSFUL CLINICAL TRIALS OF LEUKEMIA DRUGS
3.3.3. INVESTMENT FROM GOVERNMENT AND PRIVATE PLAYERS
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020
5.1.1. GLOBAL ACUTE MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.4. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY DRUGS TYPE 2014-2020
5.2.1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.1. GLOBAL ASPARAGINASE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.2. GLOBAL CLOFARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.3. GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.4. GLOBAL DOXORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.5. GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.6. GLOBAL NELARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.7. GLOBAL CORTICOSTEROIDS DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.8. GLOBAL OTHER ACUTE MYELOID LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL MYELOGENOUS LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.1. GLOBAL CYTARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.2. GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.3. GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.4. GLOBAL MITOXANTRONE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.1. GLOBAL ALEMTUZUMAB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.2. GLOBAL BENDAMUSTINE HYDROCHLORIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.3. GLOBAL IBRUTINIB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.4. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4. GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.1. GLOBAL ARSENIC TRIOXIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.2. GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.3. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.1. GLOBAL DACOGEN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.2. GLOBAL OMAPRO DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.3. GLOBAL CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.4. GLOBAL TOPOTECAN CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.5. GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.6. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETETIVE LANDSCAPE
6.1. MARKET SHARE ANAYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. CLAVIS PHARMA ASA
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. PFIZER
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. AMBIT
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. BRISTOL
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. GENZYME
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. CELGENE
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. CEPHALON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. EISAI
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. NOVARTIS
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. BIOGEN IDEC INC
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. GLAXOSMITHKLINE PLC
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. ROCHE HOLDINGS AG
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. SUNESIS PHARMACEUTICALS INC
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. TALON THERAPEUTICS INC
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. ABBOTT LABORATORIES
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. JOHNSON & JOHNSON
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. AGIOS
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. MERCK & CO.
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. ASTELLAS
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. INNATE PHARMA
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. INCIDENCE & PREVALENCE RATE
2.4. HISTORICAL ANALYSIS
2.5. PIPELINE ANALYSIS
2.5.1. ARZERRA (NOVARTIS)
2.5.2. TASIGNA (NOVARTIS)
2.5.3. CTL019(NOVARTIS)
2.5.4. BOSULIF (PFIZER)
2.5.5. INOTUZUMAB OZOGAMICIN (PFIZER)
2.5.6. SMO INHIBITOR: ACUTE MYELOID LEUKEMIA (PFIZER)
2.5.7. IMBRUVICA (JOHNSON & JOHNSON)
2.5.8. AG-221 (AGIOS)
2.5.9. LIRILUMAB (INNATE PHARMA)
2.5.10. RITUXIMAB (INNATE PHARMA)
2.6. LEUKEMIA TYPE
2.7. LEUKEMIA DIAGNOSIS
2.7.1. HEALTH HISTORY AND PHYSICAL EXAM
2.7.2. COMPLETE BLOOD COUNT (CBC)
2.7.3. BIOPSY AND BONE MARROW ASPIRATION
2.7.4. BLOOD CHEMISTRY TESTS
2.7.5. BLEEDING & CLOTTING FACTORS
2.7.6. CYTOCHEMISTRY
2.7.7. IMMUNOPHENOTYPING
2.7.8. CYTOGENTIC & MOLECULAR STUDIES
2.7.9. LUMBUR NODE BIOPSY
2.7.10. PHILADELPHIA CHROMOSOME’S PRESENCE
2.7.11. LUMBAR PUNCTURE & CEREBROSPINAL FLUID (CSF) ANALYSIS
2.7.12. IMMUNOPHENOTYPING OR PHENOTYPING BY FLOW CYTOMETRY
2.7.13. POLYMERASE CHAIN REACTION (PCR)
2.7.14. X-RAY, CT-SCAN, MRI, ULTRASOUND
2.8. KEY LEUKEMIA THERAPIES
2.8.1. CHEMOTHERAPY
2.8.2. STEM CELL TRANSPLANT
2.8.3. RADIATION THERAPY
2.8.4. TARGETED THERAPY
2.8.5. WATCHFUL WAITING
2.8.6. SUPPORTIVE THERAPY
2.8.7. OTHERS
2.9. CURRENT MARKET TRENDS
2.10. ANALYST INSIGHT
2.10.1. KEY FINDINGS
2.10.2. RECOMMENDATION
2.10.3. CONCLUSION
2.11. REGULATION
2.11.1. REGULATIONS ON CLINICAL TRIALS
2.11.1.1. FDA REGULATIONS
2.11.1.1.1. UNITED STATES
2.11.1.1.2. EUROPEAN UNION
2.11.1.1.3. CHINA
2.11.1.1.4. INDIA
2.11.1.1.5. REST OF THE WORLD
2.11.1.2. DRUG AND DEVICE REGULATIONS
2.11.1.2.1. UNITED STATES
2.11.1.2.2. EUROPEAN UNION
2.11.1.2.3. CHINA
2.11.1.2.4. INDIA
2.11.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. FDA NOD TO LEUKEMIA DRUGS ARE DRIVING THE MARKET
3.1.2. SUCCESS OF RESEARCH AND DEVELOPMENT IN LEUKEMIA THERAPEUTIC AND DRUGS
3.1.3. ADVANCEMENT IN CANCER THERAPEUTICS TO BOOST GLOBAL LEUKEMIA THERAPEUTIC MARKET
3.1.4. RISE IN ADOPTION OF PERSONALIZED MEDICINE IN THE GLOBAL LEUKEMIA THERAPEUTIC MARKET
3.1.5. INCREASE IN INCIDENCE PREVALENCE RATE OF LEUKEMIA DISEASES
3.2. RESTRAINT
3.2.1. HIGH COST OF LEUKEMIA THERAPEUTICS IS A CONCERN
3.2.2. LESS POPULAR IN EMERGING AND UNDER DEVELOPED COUNTRIES
3.3. OPPPORTUNITY
3.3.1. RISE IN ELDERLY POPULATION ACROSS THE GLOBE
3.3.2. SUCCESSFUL CLINICAL TRIALS OF LEUKEMIA DRUGS
3.3.3. INVESTMENT FROM GOVERNMENT AND PRIVATE PLAYERS
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020
5.1.1. GLOBAL ACUTE MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.2. GLOBAL CHRONIC MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.3. GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.1.4. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY DRUGS TYPE 2014-2020
5.2.1. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.1. GLOBAL ASPARAGINASE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.2. GLOBAL CLOFARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.3. GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.4. GLOBAL DOXORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.5. GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.6. GLOBAL NELARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.7. GLOBAL CORTICOSTEROIDS DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.1.8. GLOBAL OTHER ACUTE MYELOID LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2. GLOBAL MYELOGENOUS LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.1. GLOBAL CYTARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.2. GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.3. GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.2.4. GLOBAL MITOXANTRONE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.1. GLOBAL ALEMTUZUMAB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.2. GLOBAL BENDAMUSTINE HYDROCHLORIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.3. GLOBAL IBRUTINIB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.3.4. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4. GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.1. GLOBAL ARSENIC TRIOXIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.2. GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.4.3. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.1. GLOBAL DACOGEN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.2. GLOBAL OMAPRO DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.3. GLOBAL CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.4. GLOBAL TOPOTECAN CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.5. GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
5.2.5.6. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPETETIVE LANDSCAPE
6.1. MARKET SHARE ANAYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. CLAVIS PHARMA ASA
8.1.1. INTRODUCTION
8.1.2. PRODUCT PORTFOLIO
8.1.3. RECENT ACTIVITIES
8.1.4. SWOT
8.2. PFIZER
8.2.1. INTRODUCTION
8.2.2. PRODUCT PORTFOLIO
8.2.3. RECENT ACTIVITIES
8.2.4. SWOT
8.3. AMBIT
8.3.1. INTRODUCTION
8.3.2. PRODUCT PORTFOLIO
8.3.3. RECENT ACTIVITIES
8.3.4. SWOT
8.4. BRISTOL
8.4.1. INTRODUCTION
8.4.2. PRODUCT PORTFOLIO
8.4.3. RECENT ACTIVITIES
8.4.4. SWOT
8.5. GENZYME
8.5.1. INTRODUCTION
8.5.2. PRODUCT PORTFOLIO
8.5.3. RECENT ACTIVITIES
8.5.4. SWOT
8.6. CELGENE
8.6.1. INTRODUCTION
8.6.2. PRODUCT PORTFOLIO
8.6.3. RECENT ACTIVITIES
8.6.4. SWOT
8.7. CEPHALON
8.7.1. INTRODUCTION
8.7.2. PRODUCT PORTFOLIO
8.7.3. RECENT ACTIVITIES
8.7.4. SWOT
8.8. EISAI
8.8.1. INTRODUCTION
8.8.2. PRODUCT PORTFOLIO
8.8.3. RECENT ACTIVITIES
8.8.4. SWOT
8.9. NOVARTIS
8.9.1. INTRODUCTION
8.9.2. PRODUCT PORTFOLIO
8.9.3. RECENT ACTIVITIES
8.9.4. SWOT
8.10. BIOGEN IDEC INC
8.10.1. INTRODUCTION
8.10.2. PRODUCT PORTFOLIO
8.10.3. RECENT ACTIVITIES
8.10.4. SWOT
8.11. GLAXOSMITHKLINE PLC
8.11.1. INTRODUCTION
8.11.2. PRODUCT PORTFOLIO
8.11.3. RECENT ACTIVITIES
8.11.4. SWOT
8.12. ROCHE HOLDINGS AG
8.12.1. INTRODUCTION
8.12.2. PRODUCT PORTFOLIO
8.12.3. RECENT ACTIVITIES
8.12.4. SWOT
8.13. SUNESIS PHARMACEUTICALS INC
8.13.1. INTRODUCTION
8.13.2. PRODUCT PORTFOLIO
8.13.3. RECENT ACTIVITIES
8.13.4. SWOT
8.14. TALON THERAPEUTICS INC
8.14.1. INTRODUCTION
8.14.2. PRODUCT PORTFOLIO
8.14.3. RECENT ACTIVITIES
8.14.4. SWOT
8.15. ABBOTT LABORATORIES
8.15.1. INTRODUCTION
8.15.2. PRODUCT PORTFOLIO
8.15.3. RECENT ACTIVITIES
8.15.4. SWOT
8.16. JOHNSON & JOHNSON
8.16.1. INTRODUCTION
8.16.2. PRODUCT PORTFOLIO
8.16.3. RECENT ACTIVITIES
8.16.4. SWOT
8.17. AGIOS
8.17.1. INTRODUCTION
8.17.2. PRODUCT PORTFOLIO
8.17.3. RECENT ACTIVITIES
8.17.4. SWOT
8.18. MERCK & CO.
8.18.1. INTRODUCTION
8.18.2. PRODUCT PORTFOLIO
8.18.3. RECENT ACTIVITIES
8.18.4. SWOT
8.19. ASTELLAS
8.19.1. INTRODUCTION
8.19.2. PRODUCT PORTFOLIO
8.19.3. RECENT ACTIVITIES
8.19.4. SWOT
8.20. INNATE PHARMA
8.20.1. INTRODUCTION
8.20.2. PRODUCT PORTFOLIO
8.20.3. RECENT ACTIVITIES
8.20.4. SWOT
LIST OF TABLES
TABLE # 1 GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020
TABLE # 2 GLOBAL ACUTE MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL CHRONIC MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY DRUGS TYPE 2014-2020
TABLE # 7 GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL ASPARAGINASE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL CLOFARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL DOXORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL NELARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL CORTICOSTEROIDS DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL OTHER ACUTE MYELOID LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL MYELOGENOUS LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL CYTARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL MITOXANTRONE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL ALEMTUZUMAB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL BENDAMUSTINE HYDROCHLORIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL IBRUTINIB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 25 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 26 GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 27 GLOBAL ARSENIC TRIOXIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 28 GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 29 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 30 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 31 GLOBAL DACOGEN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 32 GLOBAL OMAPRO DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 33 GLOBAL CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 34 GLOBAL TOPOTECAN CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 35 GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 36 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 1 GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020
TABLE # 2 GLOBAL ACUTE MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 3 GLOBAL CHRONIC MYELOID LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 4 GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 5 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 6 GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS, BY DRUGS TYPE 2014-2020
TABLE # 7 GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 8 GLOBAL ASPARAGINASE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 9 GLOBAL CLOFARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 10 GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 11 GLOBAL DOXORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 12 GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 13 GLOBAL NELARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 14 GLOBAL CORTICOSTEROIDS DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 15 GLOBAL OTHER ACUTE MYELOID LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 16 GLOBAL MYELOGENOUS LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 17 GLOBAL CYTARABINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 18 GLOBAL DAUNORUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 19 GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 20 GLOBAL MITOXANTRONE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 21 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 22 GLOBAL ALEMTUZUMAB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 23 GLOBAL BENDAMUSTINE HYDROCHLORIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 24 GLOBAL IBRUTINIB DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 25 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 26 GLOBAL ACUTE PROMYELOCYTIC LEUKEMIA DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 27 GLOBAL ARSENIC TRIOXIDE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 28 GLOBAL IDARUBICIN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 29 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 30 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 31 GLOBAL DACOGEN DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 32 GLOBAL OMAPRO DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 33 GLOBAL CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 34 GLOBAL TOPOTECAN CLADRIBINE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 35 GLOBAL METHOTREXATE DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
TABLE # 36 GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS, 2014-2020
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. CLAVIS PHARMA ASA
2. PFIZER
3. AMBIT
4. BRISTOL
5. GENZYME
6. CELGENE
7. CEPHALON
8. EISAI
9. NOVARTIS
10. BIOGEN IDEC INC
11. GLAXOSMITHKLINE PLC
12. ROCHE HOLDINGS AG
13. SUNESIS PHARMACEUTICALS INC
14. TALON THERAPEUTICS INC
15. ABBOTT LABORATORIES
16. JOHNSON & JOHNSON
17. AGIOS
18. MERCK & CO.
19. ASTELLAS
20. INNATE PHARMA
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. CLAVIS PHARMA ASA
2. PFIZER
3. AMBIT
4. BRISTOL
5. GENZYME
6. CELGENE
7. CEPHALON
8. EISAI
9. NOVARTIS
10. BIOGEN IDEC INC
11. GLAXOSMITHKLINE PLC
12. ROCHE HOLDINGS AG
13. SUNESIS PHARMACEUTICALS INC
14. TALON THERAPEUTICS INC
15. ABBOTT LABORATORIES
16. JOHNSON & JOHNSON
17. AGIOS
18. MERCK & CO.
19. ASTELLAS
20. INNATE PHARMA
